Publicaciones en colaboración con investigadores/as de Hospital Duran i Reynals (6)

2019

  1. A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012–12 (EDALINE) study

    Investigational New Drugs, Vol. 37, Núm. 1, pp. 98-108

2017

  1. A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study

    Oncotarget, Vol. 8, Núm. 42, pp. 73144-73153

  2. Predictive and prognostic brain metastases assessment in luminal breast cancer patients: FN14 and GRP94 from diagnosis to prophylaxis

    Frontiers in Oncology, Vol. 7, Núm. DEC

2016

  1. Measurement of total and free docetaxel concentration in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry

    Journal of Pharmaceutical and Biomedical Analysis, Vol. 117, pp. 140-149

2015

  1. FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies

    Oncotarget, Vol. 6, Núm. 42, pp. 44254-44273

2010

  1. Recent advances in cancer therapy: An overview

    Current Pharmaceutical Design, Vol. 16, Núm. 1, pp. 3-10